メラノーマ治療薬の世界市場

Report Overview

The global market for melanoma therapeutics is estimated to increase from $7.4 billion in 2023 to reach $12.1 billion by 2028, at a compound annual growth rate (CAGR) of 10.2% from 2023 through 2028.

Summary:

The majority of melanoma patients are diagnosed in the localized stage of the disease, for which surgery is the mainstay of treatment. Since 2011, agents such as immunotherapies and targeted therapies have been approved to treat advanced melanoma, increasing patient survival rates. Five-year overall survival (OS) rates for metastatic melanoma have increased substantially, from less than REDACTED% before 2011, to REDACTED% to REDACTED% post-approval of novel therapies. Before novel therapies were introduced, patients received standard chemotherapy, for which the survival rates are than REDACTED% to REDACTED%. Thus, the development of novel treatments, in particular the immunomodulating monoclonal antibodies or the immune-checkpoint inhibitors (anti–CTLA-4, anti-PD-1/PD-L1) and small molecule-targeted therapies (BRAF and MEK inhibitors), has revolutionized the prognosis for patients with advanced melanoma. These targeted and immunotherapies have been approved for use either as monotherapy or as combination therapies with better outcomes.

Despite the efficacy of cancer immunotherapy targeting CTLA4 and PD1/PDL1, a considerable portion of patients (nearly REDACTED%), including those with melanoma, did not respond to immunotherapy. As a result, attention has turned towards exploring different inhibitory targets and suppressive mechanisms present within the tumor microenvironment.

The pipeline for melanoma is strong, with first-in-class molecules that have novel targets. The pipeline also focuses on personalized treatment approaches such as cell therapy and vaccines which aim at treating the disease and reduce the recurrence.

The following market factors are increasing, which is boosting market growth: prevalence of melanoma, strategic initiatives, technological advancements, product launches, early detection tools, patient advocacy groups and public awareness. However, factors restricting market growth include the high cost of treatment, stringent regulations and resistance or poor response to therapies.

The global market for melanoma treatment was estimated to reach $REDACTED billion in 2022 and is expected to reach $REDACTED billion through 2028, growing at a CAGR of REDACTED% during the forecast period. The melanoma treatment market is segment based on type of treatment, type of therapeutics, treatment by stage and by region. Major players in the market include Merck & Co., Bristol Myers Squibb and Novartis. Apart from the major players there are also small biotech companies such as Erasca, HUYABIO International and IO Biotech that have promising drug candidates in the pipeline, which should push market growth during the forecast period.

The North American region accounted for the highest share of the global market, followed by Europe. In the North American and European regions, key growth factors include increasing prevalence of melanoma, high healthcare expenditures, increasing number of drug approvals, strong pipelines, increasing public awareness and government support. Based on type of treatment, therapeutics accounted for the highest market share in 2022. Based on stage, localized stage accounted for the highest market share in 2022. In the therapeutics segment, immunotherapies accounted for the highest market share in 2022.

Report Scope:

This study investigates the melanoma treatment market. BCC Research analyzes melanoma treatment based on treatment type, cancer stage and type of therapeutics. BCC determines the current market status in each segment, examines its impact on future needs and presents growth forecasts over the next five years. The report provides a detailed analysis of the market’s drivers, challenges, and opportunities. The report also covers market projections through 2028 and analyzes market share for key market players. In its profiles of key companies, the report provides detailed information about their business segments, financials, product portfolios and recent developments. The report also discusses the market impact of the COVID-19 pandemic, emerging technologies, and new developments, ESG development and investment outlook.

Report Synopsis

Report Includes:

• 30 data tables and 18 additional tables
• An overview of the global market for melanoma treatment
• Analyses of global market trends, with data from 2020-2022, estimates for 2023, and projections of compound annual growth rates (CAGRs) through 2028
• Description of various treatment options such as chemotherapy, surgical resection, immunotherapy, and targeted therapies; and various treatment approaches for the betterment of patient’s overall health
• A look at the advancements in the genetic profiling of melanocytes and identification of novel molecules that involved in melanoma’s development
• Information on new potential therapeutic target discovery; and description of novel immune checkpoint inhibitors, adoptive cell therapy and engineered TCR therapy
• Coverage of innovation, technological advancements, and the launch of novel products from market players
• Detailed analysis of the regulatory framework and policies and product pipeline of the industry, and discussion on ESG challenges in the pharmaceutical industry and ESG practices in the melanoma treatment market
• Market share analysis of the key companies of the industry and coverage of their proprietary technologies, strategic alliances, and other key market strategies and a relevant patent analysis
• Comprehensive company profiles of the leading players of the industry, including Amgen, Roche, Merck & Co., Pfizer Inc., BMS, and Novartis AG

Table of Contents

Chapter 1 Introduction
Study Goals and Objectives
Scope of the Report
Reasons for Doing the Study
Methodology
Information Sources
Geographic Breakdown
Segmentation Breakdown
Chapter 2 Summary and Highlights
Market Outlook
Market Summary
Chapter 3 Market and Technology Background
Introduction
Risk Factors, Causes and Prevention
Symptoms
Pathophysiology and Clinical Subtypes
Prognosis
Epidemiology
Diagnosis
Biopsy
Laboratory Tests
Blood Tests
Imaging Tests
Treatment
Immunotherapy
PD-1 and PD-L1 Inhibitors
CTLA-4 inhibitors
LAG-3 Inhibitors
Interleukin-2 (IL-2, Proleukin)
Virus Therapy
BRAF inhibitors:
MEK Inhibitors
Chapter 4 Market Dynamics
Market Factors
Market Drivers
Increasing Prevalence of Melanoma
Technological Advancements and Product Launches
Strategic Initiatives
Developments in Early Detection Tools
Patient Advocacy Groups and Awareness
Market Restraints
High Cost of Treatment
Stringent Regulations
Resistance to Therapies
Market Opportunities
Chapter 5 Market Breakdown by Type
Overview
Surgery
Wide Excision
Mohs Surgery
Amputation
Lymph Node Dissection
Therapeutics
Therapeutics by Type
Radiation Therapy
Chapter 6 Market Breakdown by Disease Stage
Overview
Localized Disease
Regional Disease
Distant Disease
Chapter 7 Market Breakdown by Region
Overview
North America
Europe
Asia-Pacific
Rest of the World
Chapter 8 Sustainability: An ESG Perspective
Introduction
ESG Challenges in the Pharmaceutical Industry
ESG Practices in the Market for Melanoma Therapeutics
Environmental Initiatives
Social Initiatives
Governance Initiatives
Case Study
BCC Research Viewpoint
Chapter 9 Emerging Technologies/ Developments
Introduction
Novel Immune Checkpoint Inhibitors
Adoptive Cell Therapy
Engineered TCR Therapy
Vaccines
Targeted Therapy
Chapter 10 Regulatory Landscape and Pipeline Analysis
Regulatory Landscape
United States
Europe
Japan
Pipeline Analysis
Chapter 11 Patent Analysis
Patent Review by Year
Patent Review by Country
Patent Review
Chapter 12 Competitive Landscape
Mergers and Acquisitions
Strategic Initiatives
Competitive Analysis
Chapter 13 Company Profiles
AMGEN INC.
ASTRAZENECA PLC
BRISTOL-MYERS SQUIBB
ERASCA INC.
F. HOFFMANN-LA ROCHE AG
HUYABIO INTERNATIONAL
IOVANCE BIOTHERAPEUTICS INC.
IO BIOTECH
MERCK & CO. INC.
MODERNA INC.
NOVARTIS AG
PFIZER INC.
REGENERON PHARMACEUTICALS INC.

List of Tables
Summary Table A : Global Market for Melanoma Therapeutics, Through 2028
Summary Table B : Global Market for Melanoma Therapeutics, by Region, Through 2028 ($ Millions)
Table 1 : List of Approved Therapies for Melanoma
Table 2 : Global Melanoma Cancer Statistics, by WHO Region, 2020
Table 3 : Global Market for Melanoma Therapeutics, by Type, Through 2028
Table 4 : Recommended Margins for Surgical Excision
Table 5 : Global Market for Surgical Treatment of Melanoma, by Region, Through 2028
Table 6 : Global Market for Melanoma Therapeutics, by Region, Through 2028
Table 7 : Global Market for Melanoma Therapeutics, by Type, Through 2028
Table 8 : Global Market for Melanoma Therapeutics for Immunotherapy, by Region, Through 2028
Table 9 : Global Market for Melanoma Targeted Therapies, by Region, Through 2028
Table 10 : Global Market for Melanoma Chemotherapy, by Region, Through 2028
Table 11 : Global Market for Melanoma Radiation Therapy, by Region, Through 2028
Table 12 : Estimated Costs per Person Diagnosed with Melanoma Over a 5-Year Period, by Disease Stage, 2020
Table 13 : Global Market for Melanoma Therapeutics, by Disease Stage, Through 2028
Table 14 : Global Market for Melanoma Therapeutics for Localized Disease Stage, by Region, Through 2028
Table 15 : Global Market for Melanoma Therapeutics for the Regional Disease Stage, by Region, Through 2028
Table 16 : Global Market for Melanoma Therapeutics for the Distant Metastasis Stage, by Region, Through 2028
Table 17 : Global Market for Melanoma Therapeutics, by Region, Through 2028
Table 18 : North American Market for Melanoma Therapeutics, by Country, Through 2028
Table 19 : European Market for Melanoma Therapeutics, by Country, Through 2028
Table 20 : Estimated Incidence, Mortality and Prevalence of Melanoma in 2020
Table 21 : Asia-Pacific Market for Melanoma Therapeutics, by Country, Through 2028
Table 22 : Key ESG Issues in the Pharmaceutical Industry
Table 23 : Environmental Initiatives by Various Melanoma Therapeutics Companies
Table 24 : ESG Rankings for Companies in the Market for Melanoma Therapeutics for 2023
Table 25 : Industry-Leading Performance Across Priority ESG Ratings
Table 26 : Melanoma Pipeline: Phase II and Phase III Clinical Trials
Table 27 : Patents Issued on Melanoma Therapeutics, by Year, January 2020-August 2023
Table 28 : Patents Issued for Melanoma Therapeutics, by Country, 2020-August 2023
Table 29 : Patents Issued on Melanoma Therapeutics, by Applicant, 2020-August 2023
Table 30 : Mergers and Acquisitions, 2020-2023
Table 31 : Amgen: Financials, 2021 and 2022
Table 32 : Amgen: Marketed Products
Table 33 : BMS: Financials, 2021 and 2022
Table 34 : BMS: Marketed Products
Table 35 : BMS: News, 2019-2023
Table 36 : Roche: Financials, 2021 and 2022
Table 37 : Roche: Marketed Products
Table 38 : Roche: News, 2022
Table 39 : Merck & Co.: Financials, 2021 and 2022
Table 40 : Merck & Co.: Marketed Products
Table 41 : Merck & Co.: News, 2021-2023
Table 42 : Novartis AG: Financials, 2021 and 2022
Table 43 : Novartis AG: Marketed Products
Table 44 : Pfizer Inc.: Financials, 2021 and 2022
Table 45 : Pfizer Inc.: Marketed Products
Table 46 : Pfizer Inc.: News, 2021-2023

List of Figures
Summary Figure A : Global Market for Melanoma Therapeutics, 2020-2028
Summary Figure B : Global Market for Melanoma Therapeutics, by Region, 2020-2028
Figure 1 : Schematic Diagram of Skin Structure
Figure 2 : ABCDE Rule for Melanoma
Figure 3 : Melanoma Staging
Figure 4 : Melanoma by Stages
Figure 5 : Estimated Number of New Skin Melanoma Cases Worldwide for Both Sexes, by Age Group, 2020
Figure 6 : Melanoma Therapeutics Algorithm
Figure 7 : Global Market for Melanoma Therapeutics, by Type, 2020-2028
Figure 8 : Global Market Shares of Melanoma Therapeutics, by Type, 2022
Figure 9 : Global Market for Surgical Treatment of Melanoma, by Region, 2020-2028
Figure 10 : Timeline of FDA Treatment Approvals in Melanoma
Figure 11 : Global Market for Melanoma Therapeutics, by Region, 2020-2028
Figure 12 : Global Market for Melanoma Therapeutics, by Type, 2020-2028
Figure 13 : Global Market Shares of Melanoma Therapeutics, by Type, 2022
Figure 14 : Global Market for Melanoma Therapeutics for Immunotherapy, by Region, 2020-2028
Figure 15 : Global Market for Melanoma Targeted Therapies, by Region, 2020-2028
Figure 16 : Global Market for Melanoma Chemotherapy, by Region, 2020-2028
Figure 17 : Global Market for Melanoma Radiation Therapy, by Region, 2020-2028
Figure 18 : Global Market for Melanoma Therapeutics, by Disease Stage, 2020-2028
Figure 19 : Global Market Shares of Melanoma Therapeutics, by Disease Stage, 2022
Figure 20 : Global Market for Melanoma Therapeutics for Localized Disease Stage, by Region, 2020-2028
Figure 21 : Global Market for Melanoma Therapeutics for the Regional Disease Stage, by Region, 2020-2028
Figure 22 : Global Market for Melanoma Therapeutics for the Distant Metastasis Stage, by Region, 2020-2028
Figure 23 : Global Market for Melanoma Therapeutics, by Region, 2020-2028
Figure 24 : Global Market Shares of Melanoma Therapeutics, by Region, 2022
Figure 25 : North American Market for Melanoma Therapeutics, by Country, 2020-2028
Figure 26 : European Market for Melanoma Therapeutics, by Country, 2020-2028
Figure 27 : Asia-Pacific Market for Melanoma Therapeutics, by Country, 2020-2028
Figure 28 : RoW Market for Melanoma Therapeutics, 2020-2028
Figure 29 : ESG in Market for Melanoma Therapeutics
Figure 30 : Novartis ESG Analysis
Figure 31 : Clinical Trial Analysis
Figure 32 : Shares of Patents Issued on Melanoma Therapeutics, by Year, January 2020 to August 2023
Figure 33 : Global Market Shares of Melanoma Therapeutics, by Company, 2022
Figure 34 : Amgen: Financials, 2021 and 2022
Figure 35 : Amgen: Revenue Share, by Country/Region, 2022
Figure 36 : BMS: Financials, 2021 and 2022
Figure 37 : BMS: Revenue Share, by Business Unit, 2022
Figure 38 : BMS: Revenue Share, by Country/Region, 2022
Figure 39 : Roche: Annual Revenue, 2021 and 2022
Figure 40 : Roche: Revenue Share, by Business Unit, 2022
Figure 41 : Roche: Revenue Share, by Region, 2022
Figure 42 : Merck & Co.: Financials, 2021 and 2022
Figure 43 : Merck & Co.: Revenue Share, by Business Unit, 2022
Figure 44 : Merck & Co.: Revenue Share, by Country/Region, 2022
Figure 45 : Novartis AG: Financials, 2021 and 2022
Figure 46 : Novartis AG: Revenue Share, by Business Unit, 2022
Figure 47 : Novartis AG: Revenue Share, by Region, 2022
Figure 48 : Pfizer Inc.: Financials, 2021 and 2022
Figure 49 : Pfizer Inc.: Revenue Share, by Business Unit, 2022
Figure 50 : Pfizer Inc.: Revenue Share, by Region, 2022